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Abstract
Background: Cosmetic result following breast conserving surgery (BCS) for cancer influences quality of life and
psychosocial functioning in breast cancer patients. A preoperative prediction of expected cosmetic result following
BCS is not (yet) standard clinical practice and therefore the choice for either mastectomy or BCS is still subjective.
Recently, we showed that tumour volume to breast volume ratio as well as tumour location in the breast are
independent predictors of superior cosmetic result following BCS. Implementation of a prediction model including
both factors, has not been studied in a prospective manner. This study aims to improve cosmetic outcome by
implementation of a prediction model in the treatment decision making for breast cancer patients opting for BCS.
Methods/design: Multicentre, single-blinded, randomized controlled trial comparing standard preoperative work-up
to a preoperative work-up with addition of the prediction model. Tumour volume to breast volume ratio and tumour
location in the breast will be used to predict cosmetic outcome in invasive breast cancer patients opting for BCS. Three
dimensional (3D)-ultrasonography will be used to measure the tumour volume to breast volume ratio needed for the
prediction model. Sample size was estimated based on a 14% improvement in incidence of superior cosmetic result
one year after BCS (71% in the control group versus 85% in the intervention group). Primarily cosmetic outcome will
be evaluated by a 6-member independent panel. Secondary endpoints include; (1) patient reported outcome
measured by BREAST-Q, EORTC-QLQ-C30/BR23 and EQ-5D-5 L (2) cosmetic outcome as assessed through the BCCT.
core software, (3) radiation-induced reaction (4) surgical treatment performed, (5) pathological result and (6) cost-
effectiveness. Follow-up data will be collected for 3 years after surgery or finishing radiotherapy.
Discussion: This randomized controlled trial examines the value of a preoperative prediction model for the
treatment-decision making. It aims for a superior cosmetic result in breast cancer patients opting for BCS.
We expect improvement of patients’ quality of life and psychosocial functioning in a cost-effective way.
Trial registration: Prospectively registered, February 17th 2015, at ‘Nederlands Trialregister - NTR4997’.
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Background
For early stage breast cancer patients the goal of therapy
is to ensure both local control and breast preservation
with an optimal cosmetic outcome. The current stand-
ard of care is breast-conserving surgery (BCS) followed
by adjuvant whole breast irradiation [1–3]. Large rando-
mised clinical trials in the 80’s have shown that this treat-
ment is equivalent, in terms of overall and breast-cancer
specific survival, to a mastectomy [4]. The frequency of
BCS performed is estimated at an annual rate of 60% in
the Netherlands [5]. Oncoplastic surgery, an operation
performed jointly by a plastic surgeon and a breast-cancer
surgeon specialist, is currently more frequently performed
with the goal of obtaining the best cosmetic outcome
possible. At time of diagnosis, however, the treatment de-
cision whether to perform a mastectomy (with or without
a breast reconstruction) or BCS is often subjective.
Unfavourable cosmetic outcome following BCS is signifi-
cantly associated with decreased quality of life and psy-
chosocial functioning [6, 7]. Poor cosmetic outcome
following BCS is reported in up to 30% of breast cancer
patients [8–11]. Pre-operative knowledge of the expected
cosmetic outcome would thus be a welcome treatment
decision aid.
As previously studied by our group, independent fac-
tors for the prediction of cosmetic outcome in BCS are
tumour location and tumour volume to breast volume
ratio. This volume ratio was obtained through 3-D visu-
alisation of breast MRI images (10). Based on these fac-
tors a prediction model is made predicting the expected
cosmetic outcome for BCS. The prediction model could
aid in the treatment decision by differentiation of pa-
tients with an expected favourable cosmetic outcome
and thereby improve cosmetic outcome and patients’
quality of life.
Within this randomised trial participant will undergo an
additional 3-D ultrasonography of the affected breast.
Ultrasonography has a broad clinical applicability in breast
cancer patients and is not dependent on the use of ionizing
radiation. Measurements, obtained by the Automated
Breast Volume Scanner (ABVS) and 3-D ultrasonography
(3-D US) have previously been compared to MRI and histo-
pathological tumour size with good agreement [12, 13]. An
additional validation compared volume measurements of
the3-D US to those measured by histopathological and 3-D
MRI. Both breast and tumour volume showed high agree-
ment (unpublished data).
This study aims to improve cosmetic outcome follow-
ing BCS by using a preoperative prediction model based
on 3-D ultrasonography.
Objective
The objective of this randomized controlled trial is to com-
pare cosmetic outcome following a standard preoperative
work-up by that of the preoperative prediction model. The
hypothesis is that the addition of the preoperative predic-
tion model aids in the treatment-decision making and
therefore improves cosmetic outcome and quality of life in
patients opting for BCS.
Methods/design
Trial design
This single-blinded, multicentre, randomised controlled
trial targets women with the diagnosis of primary breast
cancer. Patients will randomly be assigned (1:1) to either
the intervention or control group after written informed
consent is given. The study is in compliance with the
Helsinki declaration. Ethical approval has been granted
by the Institutional Review Board of the Erasmus
University Medical Centre, Rotterdam, the Netherlands
(reference-number: MEC-2013-360). This trial is regis-
tered before the start of the inclusion on February 17th,
2015 (NTR 4997). Figure 1 present a flow-diagram of
the trial design.
Participants
Women with pathologically confirmed primary invasive
breast cancer (cT1–3) that are eligible and opt for BCS
will be included. Additional inclusion and exclusion cri-
teria are presented in Table 1.
Interventions
Volumetric measurements
All patients will receive an additional ultrasound
performed by the Automated Breast Volume Scanner
(ABVS– ACUSON S2000™ ABVS, Siemens Medical
Solutions, Inc., Mountain View, CA) available at the
department of Radiology, Erasmus MC Cancer Institute
[14]. A standardized scanning technique is used where 3
or 5 scans are performed (i.e. anterior-posterior, lateral
and medial view or anterior-posterior, upper lateral-,
lower lateral-, upper medial- and lower medial-
quadrant). Data from the ABVS is visualised by the ‘V-
scope’ software (department of Bioinformatics, Erasmus
MC) through an interactive 3-D image on the desktop
system. Volume measurements are performed using a
tracking system and a wireless joystick [15].
Prediction model
The tumour to breast volume ratio and the location of
the tumour in the breast are used in the prediction
model to calculate the chance of superior cosmesis in
case of BCS. If the probability exceeds the predefined
threshold primary BCS is advised. If the probability is
below the predefined threshold an alternative treatment
will be advised (i.e. oncoplastic BCS, mastectomy with
or without a breast reconstruction or neo-adjuvant
chemotherapy). The threshold is defined by modelling
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the differences in quality of life utilities between the dif-
ferent surgical strategies and the associated cosmetic
results.
Pre-operative work-up
For all randomized patients the following characteristics
will be collected (if applicable): age, body mass index
(BMI), comorbidity, previous operations, smoking status,
hormonal status, tumour morphology, TNM stadium,
post-operative complications, radiotherapy details,
chemotherapy details and hormonal therapy details.
Preoperatively all patients will be asked to complete
three questionnaires. This includes the ‘Breast Q – pre-
operative modules’ [16], the ‘European Organisation of
Fig. 1 Flow chart TURACOS trial
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research and Treatment of Cancer quality of life ques-
tionnaire (EORTC-QLQ-C30 version 3 and EORTC-
QLQ-B23 version 1)’ and ‘Euro-QoL 5D-5 L question-
naire’ (EQ-5D-5 L-version 2). All patients will preopera-
tively be discussed in multidisciplinary consultation. For
the intervention group, the optimal treatment based on
the results of the prediction model will be taken into
consideration. All patients will be blinded for the result
of the prediction model. Preoperative photographs will
be taken by a professional medical photographer. These
photographs include the 1) face-view position with the
arms down, 2) face-view with arms in the side and 3)
lateral view (90°) off the affected breast. The face view
photographs will cover the area of chin to the umbilicus
protecting the subject’s privacy and anonymity.
Follow-up
Three questionnaires will be obtained at all follow-up
visits (i.e. ‘BREAST-Q postoperative modules’, the
EORTC-QLQ-C30/B23 and the EQ-5D-5 L. Follow-up
visits will be scheduled at 3 months (T1), 1 year (T2),
and 3 year (T3) postoperatively. Photographs will be
obtained both 1 and 3 year following BCS.
Outcomes
The outcome measures are summarized in Table 2.
Primary outcome
The cosmetic outcome evaluation will be performed by
a 6-member, independent panel using the photographs.
Each panel consist of 1) a plastic surgeon/breast cancer
surgeon, 2) a general practitioner, a medical doctor, 3) a
radiation oncologist, 4) a layperson and 5) a breast can-
cer survivor. Cosmetic outcome will be evaluated using
a previously reported in-house developed questionnaire
containing 11 aggregating previous recommendations
[17] (see Additional file 1 A ‘Erasmus MC panels’ ques-
tionnaire’). Answers are scored on a four point Harvard
cosmetic scale: 0 = ‘excellent’, 1 = ‘good’, 2 = ‘moderate’,
and 3 = ‘bad’ [18].
Secondary outcome(s).
1) Patient reported outcome is measured by
the ‘BREAST-Q’, ‘EORTC-QLQ-C30/BR23’ and
‘EQ-5D-5 L’ questionnaires (T0–3).
2) Cosmetic outcome assessed by the ‘BCCT.core
software’ - INESC Porto Breast Research group
[19] based on medical photographs (T0–2-3).
3) Radiation reaction scored by the ‘Radiation Therapy
Oncology Group/European Organization for
Research and Treatment of Cancer’ – ‘RTOG/
EORTC’ (T2–3) [20].
4) Surgeries performed (T3).
5) Pathological results (T3).
6) Cost-effectiveness; direct costs will include the pre-
operative care together with the costs for (surgical)
treatment. Indirect costs will generally include
adjuvant operation(s) if applicable and costs of out-
patient clinic visits or hospitalisation (T4).
Table 2 Assessments and used instruments with timeframe indication
Outcome(s) Instrument(s) T0 T1 T2 T3
Primary endpoint
Cosmetic result Evaluation clinical photos by panel - ‘Erasmus MC panels’ questionnaire’ x x x
Secondary outcome
Cosmetic result/satisfaction with
breast assessed by patient
Breast Q - preoperative module x
Breast Q - postoperative module x x x
Patients’ Quality of life EORTC QLQ-C30/B23 questionnaire x x x x
EQ-5D-5 L questionnaire x x x x
Cosmetic result BCCT.core BCCT.core software (INESC Porto Breast Research Group) x x x
Radiation-induced reaction RTOG/EORTC x x
Surgical strategy performed Performed surgery/surgeries x
Pathological result Data of pathology reports x
Cost-effectiveness Quality-Adjusted Life Year (QALY) for direct and indirect costs x
T0 = first visit outpatient clinic, T1 = 3 months postoperative, T2 = 1 year postoperative, T3 = 3 years postoperative
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Female Recurrent breast cancer ipsilateral





Eligible for breast conserving
surgery (BCS)
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Data collection and statistical analysis
Primary study parameter
Cosmetic outcome is calculated by obtaining the mean
score for all panel members. The score per panel mem-
ber is based on the mean score off the 11 scored items
combined. Subsequently, the mean panel evaluation will
be dichotomized by defining a mean of <1.5 as superior
and a mean of >1.5 as inferior. The primary outcome is
the incidence of a superior cosmetic outcome in both
arms. Difference will be evaluated by using the Chi-square
analysis (if normally distributed) or the non-parametric
Kruskal-Wallis test (if not normally distributed).
Secondary study parameters
Cosmetic result assessed by the patient (BREAST-Q),
cosmetic evaluation through BCCT.core and radiation-
induced reaction (RTOG/EORTC) will be analysed by
comparing the intervention and control group. For
normally distributed categorical data, the Chi-Square
test will be used and the Kruskal Wallis test if not nor-
mally distributed. Continues variables as the Q-score will
be analysed making use of the Student T-test if normally
distributed or Mann-Whitney U test if not normally dis-
tributed. Pathological result will be analysed by compar-
ing the percentages of incomplete tumour excisions and
mean lumpectomy specimen size between the two study
arms. The secondary study parameters will be analysed
based on the intention-to-treat principle (i.e. including
the patients treated with mastectomy). Surgical strategies
performed will be analysed by comparing the percentages
of the different types of surgery performed by using a Chi-
square analysis if normally distributed or Kruskal-Wallis
test if not normally distributed. Patients’ quality of life,
conducted through the EORTC questionnaire/Euro-QoL
and BREAST-Q questionnaires will be presented in a
quantitative manner. Cost-effectiveness will be calculated
by Markov modelling using ‘Quality-Adjusted Life Years’
(QALY’s).
Sample size
In our previously performed retrospective study the inci-
dence of a superior cosmetic result, without interven-
tion, was 71%. An improvement of superior cosmetic
outcome to 85% was considered clinically relevant.
Expected clinical relevant difference is a 14% improve-
ment in the incidence of a superior cosmetic result as
evaluated by an independent panel. The sample size
calculation is based on comparing two proportions in in-
dependent groups by the Chi-Square test. With 80%
power and 5% significance level we need a study popula-
tion of 240 patients (120 in each arm). There is a possi-
bility that even after randomization the patient can still
undergo mastectomy instead of BCS. We expect this for
less than 25% patients in each arm, therefore we aim to
include 300 patients in total (150 in each arm).
Discussion
The literature provides limited predictive factors for an
expected favourable cosmetic outcome in breast cancer
patients opting for BCS. To objectively device a tailor-
made treatment plan this study makes use of a prediction
model [10]. This study aims to provide level 1B evidence
for the use of a preoperative prediction model for clinical
decision making to improve cosmetic results in patients
opting for BCS.
Following the inclusion of the first 30 patients (10%)
the patients’ experiences tell us that the study is well
accepted and appreciated. It is however of great import-
ance that the study is discussed by the treating surgeon
at the first or second consultation at the outpatient
clinic. By the start of inclusion up to 40% of the
approached patients declined participation. This was
mainly based on too much burdening in the preoperative
phase and an inadequate introduction of the study. If
the treating surgeon introduces the study and explains
the importance of the study in the preoperative phase
the acceptance for participation is higher. With the
allocation of multiple including centre’s in the region of
Rotterdam the inclusion rate has adequately improved
with an ongoing high acceptance of participating patients.
Preoperative assessment of patients’ quality of life and
satisfaction with their breast is currently lacking in the
literature available. Only few trials have combined post-
operative cosmetic outcome measurements by panel or
software with patient reported outcome measures
(PROMs) [21–23]. Especially an evaluation of cosmetic
outcome through time following breast surgery is scarce
[21]. By preoperatively collecting aesthetics and PROMs
a reliable understanding of the relationship between
cosmetic results and self-image or quality of life is
gained. Comparing overall health-related quality of life
(EORTC-QLQ-C30/B23 and EQ-5D-5 L) and treatment-
or surgery specific outcomes (BREAST-Q) gives a better
understanding between overall and disease-specific
quality of life [16, 24, 25]. With this knowledge, future
treatment decision making and cosmetic outcome evalu-
ation can possibly be based on PROMs. To adequately
study cosmetic outcome and their relationship to
PROM’s, standardized, reproducible and easily available
tools are needed [18, 26]. Comparing two different panel
evaluations within 68 patients following BCS our group
found almost perfect inter- and intra-observer agree-
ment. Interclass correlation coefficient showed R = 0.93,
R = 0.9 respectively for the inter- and intra-observer
agreement [unpublished data]. When comparing trials
differences in panel evaluations found are based on
panel size and the use of layperson versus experts
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[23, 27, 28]. Moreover multiple and unstandardized
questionnaires are used to obtain cosmetic outcome;
making a comparison between different trials difficult.
Based on previous recommendations of Cardoso et al.
our current study uses a questionnaire concerning the
different aspect of cosmetic outcome when evaluating
the breast by panel members [17]. The BCCT.core
software is known to evaluate asymmetry, skin colour
difference(s) and scar features based on the situation
of two identical breasts [29–31]. In line with previous
literature our group found a moderate agreement
(unpublished data) between panel and BCCT core
evaluation [22, 23]. An independent 6-member panel
will therefore assess cosmetic outcome as our primary
outcome. In summary this study aims to improve
cosmetic outcome and quality of life through the
implementation of a preoperative prediction model
for breast cancer patients opting for BCS.
Additional file
Additional file 1: Scoring list cosmetic outcome (panel evaluation).
(JPEG 218 kb)
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